Literature DB >> 24574704

Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives.

Li Ma1, Mei-Sze Chua1, Ourania Andrisani1, Samuel So1.   

Abstract

Hepatocellular carcinoma (HCC), the predominant form of adult liver malignancies, is a global health concern. Its dismal prognosis has prompted recent significant advances in the understanding of its etiology and pathogenesis. The deregulation of epigenetic mechanisms, which maintain heritable gene expression changes and chromatin organization, is implicated in the development of multiple cancers, including HCC. This review summarizes the current knowledge of epigenetic mechanisms in the pathogenesis of HCC, with an emphasis on HCC mediated by chronic hepatitis B virus infection. This review also discusses the encouraging outcomes and lessons learnt from epigenetic therapies for hematological and other solid cancers, and highlights the future potential of similar therapies in the treatment of HCC.

Entities:  

Keywords:  DNA methylation; Epigenetics; Hepatocellular carcinoma; Histone modification; lncRNA; miRNA

Mesh:

Substances:

Year:  2014        PMID: 24574704      PMCID: PMC3923010          DOI: 10.3748/wjg.v20.i2.333

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  129 in total

Review 1.  Epigenetic therapy of cancer: past, present and future.

Authors:  Christine B Yoo; Peter A Jones
Journal:  Nat Rev Drug Discov       Date:  2006-01       Impact factor: 84.694

2.  Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Ming-chun Lai; Zhe Yang; Lin Zhou; Qian-qian Zhu; Hai-yang Xie; Feng Zhang; Li-ming Wu; Lei-ming Chen; Shu-sen Zheng
Journal:  Med Oncol       Date:  2011-06-16       Impact factor: 3.064

3.  Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA.

Authors:  Katrin Panzitt; Marisa M O Tschernatsch; Christian Guelly; Tarek Moustafa; Martin Stradner; Heimo M Strohmaier; Charles R Buck; Helmut Denk; Renée Schroeder; Michael Trauner; Kurt Zatloukal
Journal:  Gastroenterology       Date:  2006-08-14       Impact factor: 22.682

4.  Anti-tumor effect of 5-aza-2'-deoxycytidine by inhibiting telomerase activity in hepatocellular carcinoma cells.

Authors:  Shuang-Fen Tao; Chang-Song Zhang; Xian-Ling Guo; Yun Xu; Shan-Shan Zhang; Jian-Rui Song; Rong Li; Meng-Chao Wu; Li-Xin Wei
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

5.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells.

Authors:  Stephanie Ma; Kwok-Wah Chan; Liang Hu; Terence Kin-Wah Lee; Jana Yim-Hung Wo; Irene Oi-Lin Ng; Bo-Jian Zheng; Xin-Yuan Guan
Journal:  Gastroenterology       Date:  2007-04-15       Impact factor: 22.682

6.  Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.

Authors:  Winnie Yeo; Hyun C Chung; Stephen L Chan; Ling Z Wang; Robert Lim; Joel Picus; Michael Boyer; Frankie K F Mo; Jane Koh; Sun Y Rha; Edwin P Hui; Hei C Jeung; Jae K Roh; Simon C H Yu; Ka F To; Qian Tao; Brigette B Ma; Anthony W H Chan; Joanna H M Tong; Charles Erlichman; Anthony T C Chan; Boon C Goh
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

7.  Interferon modulation of cellular microRNAs as an antiviral mechanism.

Authors:  Irene M Pedersen; Guofeng Cheng; Stefan Wieland; Stefano Volinia; Carlo M Croce; Francis V Chisari; Michael David
Journal:  Nature       Date:  2007-10-18       Impact factor: 49.962

8.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

Authors:  Jean-Pierre J Issa; Guillermo Garcia-Manero; Francis J Giles; Rajan Mannari; Deborah Thomas; Stefan Faderl; Emel Bayar; John Lyons; Craig S Rosenfeld; Jorge Cortes; Hagop M Kantarjian
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

Review 9.  The many faces of histone lysine methylation.

Authors:  Monika Lachner; Thomas Jenuwein
Journal:  Curr Opin Cell Biol       Date:  2002-06       Impact factor: 8.382

10.  A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.

Authors:  Laurens Kruidenier; Chun-wa Chung; Zhongjun Cheng; John Liddle; KaHing Che; Gerard Joberty; Marcus Bantscheff; Chas Bountra; Angela Bridges; Hawa Diallo; Dirk Eberhard; Sue Hutchinson; Emma Jones; Roy Katso; Melanie Leveridge; Palwinder K Mander; Julie Mosley; Cesar Ramirez-Molina; Paul Rowland; Christopher J Schofield; Robert J Sheppard; Julia E Smith; Catherine Swales; Robert Tanner; Pamela Thomas; Anthony Tumber; Gerard Drewes; Udo Oppermann; Dinshaw J Patel; Kevin Lee; David M Wilson
Journal:  Nature       Date:  2012-08-16       Impact factor: 49.962

View more
  41 in total

Review 1.  Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma.

Authors:  Yi-Gang Wang; Pan-Pan Huang; Rong Zhang; Bu-Yun Ma; Xiu-Mei Zhou; Yan-Fang Sun
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 2.  Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma.

Authors:  Laura Amicone; Alessandra Marchetti
Journal:  Transl Gastroenterol Hepatol       Date:  2018-05-02

3.  Molecular Pathogenesis of Hepatocellular Carcinoma.

Authors:  Daniel Wai-Hung Ho; Regina Cheuk-Lam Lo; Lo-Kong Chan; Irene Oi-Lin Ng
Journal:  Liver Cancer       Date:  2016-09-14       Impact factor: 11.740

4.  Clinical implication of long non-coding RNA NEAT1 expression in hepatocellular carcinoma patients.

Authors:  Sien Guo; Wenjie Chen; Yihuan Luo; Fanghui Ren; Tengfei Zhong; Minhua Rong; Yiwu Dang; Zhenbo Feng; Gang Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  Hypermethylation reduces the expression of PNPLA7 in hepatocellular carcinoma.

Authors:  Xiaojiao Zhang; Jun Zhang; Rui Wang; Shicheng Guo; Huilu Zhang; Yanyun Ma; Qingmei Liu; Haiyan Chu; Xianghong Xu; Yitong Zhang; Dongqin Yang; Jiucun Wang; Jie Liu
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

6.  Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells.

Authors:  Bin-Yong Liang; Min Xiong; Gui-Bao Ji; Er-Lei Zhang; Zun-Yi Zhang; Ke-Shuai Dong; Xiao-Ping Chen; Zhi-Yong Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31

Review 7.  Long noncoding RNAs in hepatocellular carcinoma: Novel insights into their mechanism.

Authors:  Yong-Ru Liu; Rui-Xue Tang; Wen-Ting Huang; Fang-Hui Ren; Rong-Quan He; Li-Hua Yang; Dian-Zhong Luo; Yi-Wu Dang; Gang Chen
Journal:  World J Hepatol       Date:  2015-12-08

8.  miR-128 modulates hepatocellular carcinoma by inhibition of ITGA2 and ITGA5 expression.

Authors:  Xiaohua Zhao; Yingfen Wu; Zhiping Lv
Journal:  Am J Transl Res       Date:  2015-09-15       Impact factor: 4.060

Review 9.  The "Macro" World of microRNAs in Hepatocellular Carcinoma.

Authors:  Kaveri Sidhu; Neetu Rohit Kapoor; Vijaya Pandey; Vijay Kumar
Journal:  Front Oncol       Date:  2015-03-25       Impact factor: 6.244

10.  Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.

Authors:  Hongye Jiang; Gang Ning; Yensheng Wang; Weibiao Lv
Journal:  Dis Markers       Date:  2021-06-10       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.